Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Nuclear factor‐κB (NF‐κB) is a pleiotropic transcription factor that generally enhances cellular resistance to apoptotic cell death. It has been shown to be constitutively active in some cancers and is being pursued as potential anticancer target. Sulfasalazine which is used clinically to treat Crohn’s disease has emerged as a potential inhibitor of NF‐κB and has shown promising results in two pre‐clinical studies to target primary brain tumors, gliomas. Once digested, sulfasalazine is cleaved into sulfapyridine and 5‐aminosalicylic acid (5‐ASA; mesalamine) by colonic bacteria, and the latter, too, is reported to suppress NF‐κB activity. We now show that glioma cells obtained from patient biopsies or glioma cell lines do not show significant constitutive NF‐κB activation, unless exposed to inflammatory cytokines. This does not change when gliomas are implanted into the cerebrum of severe combined immundeficient mice. Nevertheless, sulfasalazine but not its cleaved form 5‐ASA caused a dose‐dependent inhibition of glioma growth. This effect was entirely attributable to the inhibition of cystine uptake via the system x c− cystine–glutamate transporter. It could be mimicked by S‐4‐carboxy‐phenylglycine (S‐4‐CPG) a more specific system x c− inhibitor, and lentiviral expression of a constitutively active form of IκB kinase b was unable to overcome the growth retarding effects of sulfasalazine or S‐4‐CPG. Both drugs inhibited cystine uptake causing a chronic depletion of intracellular GSH and consequently compromised cellular redox defense which stymied tumor growth. This data suggests that system x c− is a promising therapeutic target in gliomas and possibly other cancers and that it can be pharmacologically inhibited by Sulfasalazine, an FDA‐approved drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842 · cited 1×
“The principal biological role of this transporter is the import of cystine which is an essential precursor for the biosynthesis of cellular antioxidant GSH, a key regulator of cellular redox status (Balendiran et al. 2004; Wu et al. 2004).”
BackgroundNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 2×
“NF-jB is a pleiotropic transcription factor that can activate over 150 genes involved in both innate and adaptive immunity, cell proliferation, anti-apoptosis, angiogenesis, and cell migration (Chen et al. 1999; Li and Verma 2002; Karin 2006).”
BackgroundSulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742 · cited 1×
“On the one hand, a growing body of literature suggests that SAS targets the NF-jB signaling pathway and suppresses apoptotic cell death (Wahl et al. 1998; Liptay et al. 1999; Weber et al. 2000; Lo et al. 2008b).”
BackgroundGout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399 · cited 3×
“On the one hand, a growing body of literature suggests that SAS targets the NF-jB signaling pathway and suppresses apoptotic cell death (Wahl et al. 1998; Liptay et al. 1999; Weber et al. 2000; Lo et al. 2008b).”
Background
Cited by
A neurocentric perspective on glioma invasion
Cuddapah, V. A., Robel, S., Watkins, S., & Sontheimer, H. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3765 · Cited by 831
Self-citationBridges, R. J., Natale, N. R., & Patel, S. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01480.x · Cited by 538
Ferroptosis and Its Role in Diverse Brain Diseases
Weiland, A., Wang, Y., Wu, W., Lan, X., Han, X., Li, Q., & Wang, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1403-3 · Cited by 467
xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression
Ji, X., Qian, J., Rahman, S. M. J., Siska, P. J., Zou, Y., Harris, B. K., Hoeksema, M. D., Trenary, I. A., Heidi, C., Eisenberg, R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0307-z · Cited by 350
xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
Liu, J., Xia, X., & Huang, P. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.021 · Cited by 347
Metadata
- Authors
- Chung, W. J., & Sontheimer, H.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2009-06-15
- Volume
- 110
- Issue
- 1
- Pages
- 182-193
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2070619895
- Cited by
- 81
- References
- 7
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB. https://app.cochat.ai/papers/10.1111/j.1471-4159.2009.06129.x
- The paper
- Chung, W. J., & Sontheimer, H. (2009). Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2009.06129.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.